NCT00600496 2025-11-13A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)AstraZenecaPhase 1 Active not recruiting140 enrolled
NCT00739453 2024-11-20A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)Astellas Pharma IncPhase 1 Completed95 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01115803 2019-02-05A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid TumorsEli Lilly and CompanyPhase 1 Terminated29 enrolled 19 charts
NCT00030498 2013-01-16Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionNational Cancer Institute (NCI)Phase 1 Completed75 enrolled